medigraphic.com
ISSN 1028-4818 (Electronic)

2019, Number 5

<< Back Next >>

Mul Med 2019; 23 (5)

Adverse events associated with vaccination in children under 2 years of age. Granma Province. 2014-2018

Chong OO, Pérez AMÁ, Barrero AME

Language: Spanish
References: 10
Page: 940-957
PDF size: 391.51 Kb.


ABSTRACT

A descriptive, cross-sectional study was conducted with the aim of describing adverse events associated with vaccination in children under 2 years of age in Granma province during the period January 2014 to January 2018. The universe consisted of 2074 reports reported to the surveillance system through Surveys established by the MINSAP Extended Immunization Program (Model 84-30-2). The most affected age group was 1 to 6 months (65.0%), female predominance (54.1%), the Heberpenta vaccine was the highest reactogenicity with a specific rate of 813.8 x 105 doses applied, mild common events prevailed (fever, local reaction, irritability) with 91.1%. According to the application site the largest reports of adverse events corresponded to the use of the intramuscular pathway and the application in the anterolateral face of the thigh (CALM), with more than 95.0% of the cases reported. With all these results it was concluded that adverse events were more common in infants, predominantly systemic adverse events and these the most prevalent fever. Of local adverse events, pain and induration at the injection site were the most common events. There were no noticeable differences by sex. There were no aftermath, no deaths.


REFERENCES

  1. Castillo M. Epidemiología. La Habana: Pueblo y Educación; 1984.

  2. Galindo Santana BM, Peláez Sánchez R, Galindo Sardiña MA, León Villafuerte M, Concepción Díaz D, Estruch Rancaño L. Vigilancia activa de eventos adversos a la vacuna Pandenrix para prevenis la influenza AH1N1 en Cuba. Rev Cubana Med Trop 2011; 63(3): 231-8.

  3. Galindo Santana B, Arroyo Rojas L, Concepción Díaz D. Seguridad de las vacunas y su repercusión en la población. Rev Cubana Salud Pública 2011; 37(1): 149-58.

  4. Organización Mundial de la Salud. Vacunación Segura. Cómo enfrentar los eventos supuestamente atribuidos a la vacunación e inmunización. [Internet]. Washington DC: OPS; 2002. [Citado 19/4/2016]. Disponible en: https://www.who.int/immunization_safety/publications/aefi/en/vacunacion_segura_S.pdf

  5. Organización Panamericana de la Salud. Vacunación segura: Módulo IV Aspectos técnicos y clínicos de los eventos supuestamente atribuibles a la vacunación o inmunización (ESAVI). Washington, DC: OPS; 2007.

  6. Álvarez García FJ, Van Esso Arbolave D. Intervalos y compatibilidad entre las vacunas [Internet]. España: Comited Asesorde Vacunas; 2015. [Citado 11 Oct 2018]. Disponible en: https://vacunasaep.org/profesionales/intervalos-y-compatibilidad-entre-vacunas

  7. Álvarez García F. Características generales de las vacunas. Pediatr Integral 2015; 19(10): 666–74.

  8. Comité Asesor de Vacunas de la AEP. Seguridad de las vacunas. Contraindicaciones y precauciones. Manual de vacunas en línea de la AEP. [Internet]. Madrid: AEP; 2016 [Citado 24/6/2016]. Disponible en: https://vacunasaep.org/documentos/manual/cap-3

  9. Comité Asesor de Vacunas de la AEP. Manual de vacunas en línea de la AEP. [Internet]. Madrid: AEP; 2015 [Citado 24/6/2016]. Disponible en: https://vacunasaep.org/documentos/manual/manual-de-vacunas

  10. Organización Panamericana de la Salud. Sistemas de notificación de incidentes en América Latina [Internet]. Washington, D.C: OPS; 2013. [Citado 11/10/2018]. Disponible en: https://www.paho.org/hq/index.php?option=com_content&view=article&id=8557:2013-sistemas-notificacion-incidentes-america-latina-2013&Itemid=3562&lang=es




2020     |     www.medigraphic.com